Omicron

• The Company attributed the result, in part, to the “dynamic” development of the pandemic, which “caus[ed] a re-phasing of orders and .
• A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
• If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
• of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

• Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or “the Company”) (NASDAQ: BNTX) and certain of its officers.
• BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
• or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
• Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

• For the year to December 2023, in England COVID rates peaked at around one in 24 people.
• During the same month, Singapore also experienced record COVID cases and a spike in hospitalisations.
• COVID, then, is still a major public health problem, accounting for 10,000 deaths in 50 countries and a 42% increase in hospitalisations during December 2023 alone.
• COVID may not be a global health emergency at the moment, but it is still killing and harming far too many people worldwide.

How to fight COVID complacency

• In future campaigns, boosters should be offered more broadly.
• Cleaner air is essential for public health and will have benefits that extend beyond COVID.
• Good ventilation can not only reduce the spread of COVID and other respiratory viruses, but can generally help reduce indoor air pollution, and can even improve things such as school attendance and concentration in the classroom.

• Existing evidence suggests that masks do work to help reduce the transmission of COVID.
• We can still live with COVID and at the same time respect, and try to reduce, the harm it can cause.

Simon Nicholas Williams has received funding from Senedd Cymru, Public Health Wales and the Wales Covid Evidence Centre for research on COVID-19, and has consulted for the World Health Organization. However, this article reflects the views of the author only, in his academic capacity at Swansea University, and no funding or organizational bodies were involved in the writing or content of this article.

• All authorized SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralization potency against the currently circulating variants.
• ExeVir’s XVR012, a cocktail of XVR013m and XVR014, targets three distinct epitopes highly conserved across the broad sarbecovirus subgenus of Coronaviridae to minimize the risk for viral escape.
• XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein.
• ExeVir is currently gearing up to start the clinical development of both the combination XVR012, as well as its individual components XVR013m and XVR014.